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Glucagon-like peptide-1 (GLP-1) receptor agonists are an effective treatment approach for type 2 diabetes. Recently, anti-
inflammatory effects of GLP-1 receptor agonists have also been reported. Lipopolysaccharide (LPS) induces inflammation
and osteoclast formation. In this study, we investigated the effect of exendin-4, a widely used GLP-1 receptor agonist, in
LPS-induced osteoclast formation and bone resorption. LPS with or without exendin-4 was administered on mouse calvariae
by daily subcutaneous injection. The number of osteoclasts, the ratio of bone resorption pits, and the level of C-terminal
cross-linked telopeptide of type I collagen (CTX) were significantly lower in LPS- and exendin-4-coadministered mice than
in mice administered with LPS alone. RANKL and TNF-α mRNA expression levels were lower in the exendin-4- and LPS-
coadministered group than in the LPS-administered group. Our in vitro results showed no direct effects of exendin-4 on
RANKL-induced osteoclast formation, TNF-α-induced osteoclast formation, or LPS-induced RANKL expression in stromal
cells. Conversely, TNF-α mRNA expression was inhibited in the exendin-4- and LPS-cotreated macrophages compared with
cells treated with LPS alone. These results indicate that the GLP-1 receptor agonist exendin-4 may inhibit LPS-induced
osteoclast formation and bone resorption by inhibiting LPS-induced TNF-α production in macrophages.
1. Introduction
The prevalence of type 2 diabetes mellitus is increasing
worldwide, and the condition has become a major public
health problem. Individuals with type 2 diabetes have been
shown to have a higher risk of bone fracture compared with
individuals without type 2 diabetes [1]. This higher risk
might be associated with the pathobiology of type 2 diabe-
tes itself; however, the underlying mechanisms remain
unclear [2]. Additionally, increased bone fracture risk is a
consequence of therapeutic regimen used to treat hypergly-
cemia [3]. For example, patients treated with thiazolidine-
diones and human recombinant insulin have been shown
to have an increased bone fracture risk [4–7]. Conversely,
treatment with metformin is related to decreased bone frac-
ture risk [8].
Osteoclast recruitment is crucial to the pathogenesis of
diseases involving bone erosion, such as rheumatoid arthri-
tis [9]. Osteoclasts derived from bone marrow cells are
responsible for bone resorption and remodeling [10]. Recep-
tor activator of NF-kB ligand (RANKL) and macrophage
colony-stimulating factor (M-CSF) are two key factors
required for osteoclast formation and activation [11]. Inde-
pendent of RANKL, tumor necrosis factor- (TNF-) α has also
been reported to induce osteoclast formation in vitro [12–14]
and in vivo [15, 16].
Lipopolysaccharide (LPS) strongly induces inflammation
and inflammatory bone loss [17–21]. LPS has also been
found to induce production of proinflammatory cytokines,
such as TNF-α, from macrophages or other cells at the site
of inflammation [22, 23]. Such proinflammatory cytokines
have been reported to be involved in LPS-induced osteoclast
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formation and bone destruction in in vivo and in vitro studies
[18, 24–27]. Additionally, LPS can stimulate osteoblasts to
produce or secrete RANKL [28].
Glucagon-like peptide-1 (GLP-1), an intestinal hormone,
plays important roles in blood glucose control and prolifera-
tion of pancreatic islet β-cells [29, 30]. GLP-1 receptor-
deficient mice were reported to exhibit osteopenia and
increased osteoclast formation, suggesting that the GLP-1
signaling has an inhibitory effect of bone resorption on bone
metabolism [31]. An anabolic effect of GLP-1 on bonemetab-
olism has also been proposed. GLP-1 receptor activation has
been shown to induce bone formation in streptozotocin-
induced diabetic and fructose-stimulated insulin-resistant
rats [32].
It has been reported that patients with type 2 diabetes
have high risk of bone fracture [1, 2]. Furthermore, antidia-
betic medicines such as thiazolidinediones may further pro-
mote bone resorption and increase fracture risk [33–35].
However, a recent meta-analysis has reported that GLP-1
receptor agonist treatment does not affect fracture risk in
type 2 diabetic patients [36, 37].
The anabolic and antiresorptive effects of GLP-1 recep-
tor suggest that GLP-1 receptor signaling may be a promis-
ing therapeutic target for osteoporosis or other osteolytic
bone diseases; such a therapeutic approach would be facili-
tated by the fact that the first commercially available GLP-1
receptor agonist, exendin-4, has already been approved for
the treatment of diabetes for over 10 years [38]. Exendin-
4 shares similar structural and functional properties to
GLP-1 but is resistant to the degradation by dipeptidyl pep-
tidase-IV, which can degrade GLP-1 immediately in the
blood [39]. The extended half-life, improved pharmacoki-
netics, and high potency of exendin-4 make it suitable for
clinical use [39–41].
In the present study, we investigated the effects of
exendin-4 on LPS-induced osteoclast formation and bone
remodeling in mice.
2. Materials and Methods
2.1. Animals and Reagents. Eight- to ten-week-old male
C57BL6/J mice were obtained from CLEA Japan (Tokyo,
Japan) and maintained at our animal facility. All animal care
and experiments were conducted according to Tohoku Uni-
versity rules and regulations. Four mice were randomly
assigned to each experimental group. Both Escherichia coli
LPS and exendin-4 were purchased from Sigma-Aldrich (St.
Louis, MO).
2.2. Histological Analysis. A previous in vivo study demon-
strated that daily subcutaneous injections of 100μg LPS to
mouse calvariae for 5 days effectively induced osteoclast for-
mation [42]. Therefore, we followed the same protocol, dose,
and LPS administration period in this study. The mice were
divided into four experimental groups and subjected to daily
subcutaneous injections on the calvaria with phosphate-
buffered saline (PBS, negative control group), LPS alone
(100μg/day, positive control group), LPS (100μg/day) and
exendin-4 (20μg/day), and exendin-4 alone (20μg/day)
for 5 days. All mice calvariae were excised immediately after
sacrifice on the sixth day. The calvariae were fixed in 4%
PBS-buffered formaldehyde at 4°C overnight and then
demineralized with 14% ethylenediaminetetraacetic acid
(EDTA) at room temperature for three days. Each calvaria
was cut into three pieces perpendicular to the sagittal suture.
Samples were then embedded in paraffin and cut into 5μm
sections using a microtome. The paraffin sections were
stained with tartrate-resistant acid phosphatase (TRAP)
solution prepared by mixing acetate buffer (pH5.0), naph-
thol AS-MX phosphate (Sigma Chemical, St. Louis, MO,
USA), Fast Red Violet LB Salt (Sigma), and 50mM sodium
tartrate. The sections were counterstained with hematoxylin.
Osteoclasts were defined in this study as TRAP-positive
cells with three or more nuclei. We counted the number
of osteoclasts only at the suture mesenchyme of the sagittal
suture in all slides according to the method in our previous
work [43].
2.3. Preparation of Osteoclast Precursors for Osteoclastogenesis.
To isolate bone marrow cells from C57BL6/J mice, femora
and tibiae were aseptically removed after sacrifice. The
epiphyses of these long bones were removed, and the bone
marrow was flushed into a sterile Petri dish with a 25-gauge
needle and 10ml syringe filled with culture medium. The
bone marrow was then filtered with a 40μm nylon cell
strainer (Falcon, USA) and centrifuged. The harvested cells
were incubated in a culture medium comprising alpha-
modified minimal essential medium (α-MEM; Sigma) con-
taining 10% fetal bovine serum (FBS), 100 IU/ml penicillin
G (Meiji Seika, Tokyo, Japan), and 100μg/ml streptomycin
(Meiji Seika), with M-CSF added. Nonadherent cells were
removed by washing with PBS, and adherent cells were har-
vested using trypsin-EDTA solution (Sigma-Aldrich). The
harvested cells were seeded and further cultured in the pres-
ence of M-CSF. Adherent cells were used as osteoclast pre-
cursors in this study as previously reported [43]. Osteoclast
precursors were seeded at 5× 104 cells per 200μl of medium
in a 96-well plate and cultured in medium containing M-CSF
alone (100 ng/ml), M-CSF (100 ng/ml) and RANKL (100 ng/
ml) or TNF-α (100 ng/ml), M-CSF (100 ng/ml) and RANKL
(100 ng/ml) or TNF-α (100 ng/ml) with exendin-4 (100 ng/
ml), and M-CSF (100 ng/ml) with exendin-4 (100 ng/ml),
for 5 days. The cultured cells were then fixed with 10% for-
malin for 30min. After fixation, the cells were permeabilized
with 0.2% Triton X-100 for 5min at room temperature,
then incubated in TRAP staining solution prepared as
described above. TRAP-positive cells with three or more
nuclei were considered to be osteoclasts and were counted
under a light microscope.
2.4. Preparation of Bone Marrow Stromal Cells. Bone marrow
cells were obtained by the method described above and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma) containing 10% FBS, 100 IU/ml penicillin G (Life
Technologies, Carlsbad, CA), and 100μg/ml streptomycin
(Life Technologies) for two weeks. Then the culture disks
were washed vigorously with PBS to remove nonadherent
2 Journal of Immunology Research
cells. Adherent cells were used as stromal cells in this study as
previously reported [43].
2.5. Isolation of Murine Macrophages. Macrophages were
obtained from the peritoneal cavity of mice. To obtain resi-
dent macrophages under resting conditions, we injected
5ml of sterile ice-cold PBS (pH7.4) into the peritoneal cavity
and aspirated the fluid to harvest peritoneal cells. The cells
were washed twice with α-MEMmedium (Sigma) containing
10% FBS. After 1 hour of culture, nonadherent cells were
removed, and after 24 hours of culture, adherent cells were
harvested and used as macrophages.
2.6. Isolation of RNA and Real-Time RT-PCR Analysis. Cal-
variae from the in vivo experiments were frozen in liquid
nitrogen and crushed by Micro Smash MS-100R (Tomy
Seiko, Tokyo, Japan) in 800μl TRIzol reagent (Invitrogen,
Carlsbad, CA) for each sample. Total RNA was extracted
with an RNeasy mini kit (Qiagen, Valencia, CA) according
to the manufacturer’s protocol. For the in vitro experiments,
bone marrow stromal cells or macrophages were incubated in
culture medium supplemented with PBS, LPS (100 ng/ml),
LPS (100 ng/ml) and exendin-4 (100 ng/ml), and exendin-4
(100 ng/ml). After three days of culture, total RNA was
isolated from adherent cells. Total RNA of stromal cells or
peritoneal macrophages was isolated using an RNeasy mini
kit (Qiagen). cDNA was synthesized for each sample from
2μg total RNA with oligo-dT primers (Invitrogen) and
reverse transcriptase in a total volume of 20μl. The corre-
sponding expression levels of RANKL and TNF-α mRNA
were evaluated by real-time RT-PCR using a Thermal Cycler
Dice Real Time System (Takara, Shiga, Japan). Each reaction
comprised a total volume of 25μl containing 2μl cDNA and
23μl of a mixture of SYBR Premix Ex Taq (Takara) and
50 pmol/μl primers. The PCR cycling conditions were as fol-
lows: 95°C for 10 s for initial denaturation followed by 45–60
amplification cycles, with each cycle comprising a denatur-
ation step of 95°C for 5 s and then an annealing step of 60°C
for 30 s. Relative expression levels of TNF-α and RANKL
mRNAs were calculated by normalization to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mRNA levels. The
primer sequences used for cDNA amplification were as fol-
lows: 5′-GGTGGAGCCAAAAGGGTCA-3′ and 5′-GGGG
GCTAAGCAGTTGGT-3′ for GAPDH; 5′-AGGCGGTGC
TTGTTCCTCA-3′ and 5′-AGGCGAGAAGATGATCTGA
CTGCC-3′ for TNF-α; and 5′-CCTGAGGCCAGCCATTT-
3′ and 5′-CTTGGCCCAGCCTCGAT-3′ for RANKL as
already reported [43].
2.7. Micro-CT Imaging and Analysis for Bone Destruction
Area. We obtained mouse calvariae immediately after
sacrifice. The calvariae were fixed in 4% PBS-buffered
formaldehyde at 4°C for 3 days. To assess the bone resorption
pits on the calvariae, samples were washed thoroughly with
PBS and scanned with microfocus computed tomography
(ScanXmate-E090, Comscan, Kanagawa, Japan). TRI/3D-
BON64 software (RATOC System Engineering, Tokyo,
Japan) was used to create three-dimensional images of the
mouse calvariae, and the ratio of bone resorption area to total
area was measured by ImageJ (NIH, Bethesda, MD) as previ-
ously reported [43].
2.8. Measurement of Serum CTX (C-Terminal Cross-Linked
Telopeptide of Type I Collagen) Value. Blood was collected
with microhematocrit tubes from the orbital sinuses of the
mice after 5 days of daily administration of PBS, LPS with
or without exendin-4, or exendin-4 alone. The levels of
CTX were determined using a mouse C-terminal telopeptide
of type I collagen assay kit (IDS, Tyne and Wear, UK). Levels
of C-terminal telopeptide of type I collagen were assessed by
measuring absorbance at 450nm with a microplate reader
(Remote Sunrise; Tecan, Japan), with 620nm as the refer-
ence wavelength.
2.9. Cell Viability Assay for Osteoclast Precursors. Osteoclast
precursors were seeded in a 96-well plate (1× 104 cells in
200μl medium per well) and incubated with M-CSF
(100 ng/ml) with or without exendin-4 (100 ng/ml). After 5
days of incubation, the cells were washed with PBS and cul-
tured in 100μl culture medium of each well. Four replicates
were assessed for each sample. Then, 10μl cell counting kit-
8 (Dojin, Kumamoto, Japan) solution was added to each well,
and the plate was further incubated for 2 h at 37°C. Absor-
bance at 450nm was measured by a microplate reader for
each well as previously reported [43].
2.10. Statistical Analysis. Data are expressed as means± stan-
dard deviation. The statistical significance of differences
between groups was determined by Scheffe’s test. P < 0 05
was considered significant.
3. Results
3.1. In Vivo Inhibitory Effect of Exendin-4 on LPS-Induced
Osteoclast Formation. We injected LPS with or without
exendin-4 on mouse calvariae to analyze the effect of
exendin-4 on LPS-induced osteoclast formation in vivo. After
LPS administration for 5 consecutive days, many large multi-
nucleated osteoclasts were observed within the suture mesen-
chyme in the histological sections. However, the mean
number of osteoclasts was significantly lower in the LPS-
and exendin-4-coadministered group than in the group
administered with LPS alone (Figures 1(a) and 1(b)).
3.2. In Vivo Inhibitory Effect of Exendin-4 on LPS-Induced
Bone Resorption. The mouse calvariae were scanned with
microfocus computed tomography, and the amount of bone
resorption areas was compared between each group. Many
bone destruction defects were noted in the LPS group. The
ratio of the bone resorption area to the total area was
significantly higher in the LPS-administered group than in
the PBS-administered and exendin-4-administered groups.
Moreover, the LPS- and exendin-4-coadministered groups
demonstrated less bone destruction than the group adminis-
tered with LPS alone (Figures 2(a) and 2(b)). Serum levels of
C-terminal telopeptide of type I collagen (CTX), a marker of
bone resorption, in mouse serum samples were analyzed by a
mouse CTX assay kit. The serum CTX level in the LPS-alone-
administered group was higher than PBS-administered
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group. However, the serum CTX level in the LPS- and
exendin-4-coadministered group was lower than that in the
LPS-alone-administered group (Figure 2(c)).
3.3. In Vivo Inhibitory Effect of Exendin-4 on the Expression of
LPS-Induced Osteoclast-Related Cytokines (TNF-α and
RANKL). Bone chips from mouse calvariae were analyzed
by real-time RT-PCR to measure expression levels of TNF-α
and RANKL mRNA. TNF-α and RANKL mRNA levels were
elevated in the LPS-administered group compared with the
PBS-administered group. Conversely, TNF-α and RANKL
mRNA expression levels were reduced in the exendin-4-
and LPS-coadministered group compared with the LPS-
administered group (Figure 3).
3.4. Exendin-4 Cannot Affect RANKL-Induced Osteoclast
Formation, TNF-α-Induced Osteoclast Formation, Cell
Viability of Osteoclast Precursor Cells, and LPS-Induced
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Figure 1: In vivo effect of exendin-4 on lipopolysaccharide- (LPS-) induced osteoclast formation. (a) Histological sections of mouse calvariae
after 5-day daily supracalvarial injections with phosphate-buffered saline (PBS), LPS (100 μg/day), LPS (100 μg/day) with exendin-4 (20 μg/
day), and exendin-4 (20μg/day). Tartrate-resistant acid phosphatase (TRAP) staining and hematoxylin counterstaining were performed.
TRAP-positive cells were stained dark red. (b) The numbers of TRAP-positive cells in the suture mesenchyme of calvaria from the mouse
groups administered with PBS, LPS, LPS with exendin-4, and exendin-4, respectively. Data is expressed as means± standard deviation
(SD). Statistical significance were determined by Scheffe’s test (n = 4; ∗∗p < 0 01).
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Figure 2: Exendin-4 inhibited LPS-induced bone resorption in vivo. (a) 3D reconstructed images of calvariae from micro-CT scanning. Mice
were subjected to 5-day daily subcutaneous injections on the calvariae with PBS, LPS (100 μg/day) with or without exendin-4 (20μg/day), and
exendin-4 (20 μg/day), and calvariae were excised on the sixth day. The red dots indicate areas of bony destruction. (b) Ratio of bone
destruction area to total bone area. Data is expressed as means± SD (n = 4; ∗p < 0 05, ∗∗p < 0 01). The statistical significance of differences
was determined by Scheffe’s test. (c) Serum levels of C-terminal telopeptide of type I collagen (CTX) determined by a mouse CTX assay
kit. Data is expressed as means± SD. The statistical significance of differences was determined using Scheffe’s test (n = 4; ∗∗p < 0 01).
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RANKL Expression in Stromal Cells. To investigate whether
exendin-4 affects osteoclast precursor cells directly, we ana-
lyzed the effects of exendin-4 on RANKL-induced osteoclast
formation, TNF-α-induced osteoclast formation, and viabil-
ity of osteoclast precursors. There were large numbers of
TRAP-positive cells among osteoclast precursor cells
cultured with M-CSF and RANKL or TNF-α. Likewise,
TRAP-positive cells were also observed among the osteoclast
precursor cells cultured with M-CSF and RANKL or TNF-α
in the presence of exendin-4 (Figures 4(a) and 4(b)).
Additionally, there was no evident difference in cell viabil-
ity between the two cultures after 5 days of culture
(Figure 4(c)). These results indicate that the inhibitory
effect of exendin-4 may not be related to a direct action of
exendin-4 on the proliferation and differentiation of
osteoclast precursors.
We next evaluated whether exendin-4 inhibited LPS-
induced RANKL expression in stromal cells in vitro. RANKL
mRNA expression levels were higher in LPS-treated stromal
cells than in control and exendin-4-treated stromal cells.
However, stromal cells treated with both LPS and exendin-
4 demonstrated similar RANKL mRNA expression levels to
those treated with LPS alone (Figure 4(d)). These results
show that the inhibitory effect of exendin-4 may not be
related to a direct action of exendin-4 on RANKL expression
in stromal cells.
3.5. Exendin-4 Suppresses LPS-Induced TNF-α Expression in
Macrophages. Real-time RT-PCR was performed to analyze
TNF-α mRNA expression levels. TNF-α mRNA expression
was elevated in macrophages treated with LPS alone com-
pared with those treated with PBS. Conversely, TNF-α
mRNA expression was inhibited in the exendin-4- and
LPS-treated macrophages, compared with those treated with
LPS alone (Figure 5).
4. Discussion
In the present study, we evaluated the effect of the GLP-1
receptor agonist exendin-4 on LPS-induced osteoclast forma-
tion and bone-resorption in vivo. We found that the GLP-1
receptor agonist inhibited LPS-induced osteoclast formation
and bone resorption and also suppressed LPS-induced
RANKL and TNF-α expression in vivo. Conversely, the
GLP-1 receptor agonist did not directly inhibit RANKL-
induced osteoclast formation, TNF-α-induced osteoclast for-
mation, osteoclast precursor cell viability, or LPS-induced
RANKL expression in stromal cells in vitro. However, the
GLP-1 receptor agonist inhibited LPS-induced TNF-α
expression in macrophages in vitro.
GLP-1 plays a crucial role in blood glucose control. To
simulate the effect of GLP-1, many GLP-1 analogues and
GLP-1 receptor agonists have been developed. The amino
acid sequence of the GLP-1 receptor agonist exendin-4 is a
modified version of the sequence of GLP-1. Exendin-4 is
resistant to degradation by dipeptidyl peptidase-IV and has
a much longer plasma half-life than GLP-1 [40], which has
a half-life of less than two minutes [39, 41]. The extended
half-life, improved pharmacokinetics, and high potency of
exendin-4 make it suitable for clinical use [39, 40].
GLP-1 receptor-deficient mice have been reported to
exhibit increased bone breakdown, which indicates that
GLP-1 receptor signaling is essential to inhibition of osteo-
clast formation and bone resorption [31]. In the present
study, exendin-4 inhibited LPS-induced osteoclast forma-
tion. Daily injections of 20μg of exendin-4 for 5 days (a
total of 100μg) were sufficient to inhibit LPS-induced oste-
oclast formation in vivo. We also evaluated the inhibitory
effect of exendin-4 on LPS-induced bone resorption. The
extent of bone destruction was determined by the ratio of
the destroyed bone area to total bone area, assessed by
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Figure 3: Exendin-4 suppressed expression of LPS-induced tumor necrosis factor- (TNF-) α and receptor activator of NF-kB ligand
(RANKL) in vivo. TNF-α and RANKL mRNA levels in mouse calvariae were determined using real-time RT-PCR. Total RNA was
isolated from mouse calvariae after 5-day daily supracalvarial injections with PBS, LPS (100 μg/day) with or without exendin-4
(20 μg/day), and exendin-4 alone (20 μg/day). TNF-α and RANKL mRNA levels were normalized to the expression of glyceraldehyde
3-phosphate dehydrogenase (GAPDH). Data is expressed as means± SD. The statistical significance of differences was determined using
Scheffe’s test (n = 4; ∗p < 0 05, ∗∗p < 0 01).
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Figure 4: Exendin-4 had no effect on RANKL-induced osteoclast formation, TNF-α-induced osteoclast formation, osteoclast precursor cell
viability, or LPS-induced RANKL expression in stromal cells in vitro. (a) Microscopic images and numbers of TRAP-positive cells. Osteoclast
precursors were treated with macrophage colony-stimulating factor (M-CSF) alone, M-CSF with RANKL, M-CSF with RANKL and exendin-
4, and M-CSF with exendin-4 for 5 days, then stained with TRAP solution. (b) Microscopic images and numbers of TRAP-positive cells.
Osteoclast precursors were treated with M-CSF alone, M-CSF with TNF-α, M-CSF with TNF-α and exendin-4, and M-CSF with exendin-
4 for 5 days, then stained with TRAP solution. (c) Cell viability of osteoclast precursor cells treated with M-CSF alone and M-CSF with
exendin-4 for 5 days. Cell viability was determined by cell counting kit-8. Data is presented as percentage activity relative to the activity in
the culture with M-CSF alone and is expressed as means± SD. (d) RANKL mRNA expression levels in stromal cells determined by real-
time RT-PCR method. Total RNA was extracted from stromal cells that were cultured with PBS, LPS with or without exendin-4, and
exendin-4 alone, respectively. RANKL mRNA levels were normalized to that of GAPDH. Statistical significance of differences was
determined by Scheffe’s test (n = 4; ∗∗P < 0 01).
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microfocus computed tomography imaging, and by the
serum CTX value of each experimental group. We found
that the extent of bone destruction was significantly lower
in the LPS- and exendin-4-coadministered group than the
group administered with LPS alone. Our results suggest that
exendin-4 inhibited LPS-induced osteoclast formation and
bone resorption in vivo.
In this study, we administered 20μg/day exendin-4 for 5
days, injected into the supracalvaria. Although previous
rodent studies used 20μg/kg exendin-4 daily for 4 weeks
[41, 44], we opted to use a higher dose to enhance the inhib-
itory effects of exendin-4. Further investigation using clini-
cally relevant doses is needed.
Our findings prompted us to explore the mechanisms
contributing to the inhibition of LPS-induced osteoclast
formation and bone resorption. We considered two possible
mechanisms. First, we considered whether exendin-4 inhib-
ited LPS-induced expression of inflammatory cytokines
related to osteoclast formation, such as TNF-α and RANKL.
Many studies have indicated that LPS induces TNF-α and
RANKL in vivo [28, 45]. RANKL is an essential cytokine
for osteoclast formation [10], and it has been reported that
TNF-α also can induce osteoclast formation in vivo [15, 16].
Therefore, it is reasonable to suspect that if levels of both of
these cytokines are decreased, osteoclast formation will be
inhibited. In the present study, TNF-α and RANKL mRNA
levels were elevated in the LPS-administered mice. However,
thisLPS-induced increase inTNF-αandRANKLmRNAlevels
was inhibited in the exendin-4- and LPS-coadministered
group, compared with the group administered LPS only. This
suggests that one of the mechanisms underlying the inhibi-
tory effect of exendin-4 on LPS-induced osteoclast formation
is the inhibition of LPS-induced osteoclast-related cytokines.
The other mechanism that we considered was that exendin-4
directly inhibited RANKL- and TNF-α-induced osteoclast
formation. In the present study, we investigated whether
exendin-4 exerted its inhibitory effect on osteoclasts by
directly acting on osteoclast precursors. However, exendin-
4 did not inhibit RANKL- or TNF-α-induced differentiation
of osteoclast precursor cells into osteoclasts. Moreover, we
investigated whether exendin-4 inhibited osteoclast precur-
sor cell viability. We observed no difference in cell viability
between the two groups after 5 days of culture. These results
suggest that the inhibitory effect of exendin-4 on osteoclast
formation is not due to a direct action of exendin-4 on
osteoclast precursors. We then evaluated whether exendin-4
inhibited LPS-induced RANKL expression in stromal cells.
Exendin-4 also failed to inhibit LPS-induced RANKL expres-
sion in stromal cells. This indicates that inhibition of RANKL
expression by exendin-4 may not be due to a direct action of
exendin-4 on stromal cells. Finally, we evaluated whether
exendin-4 inhibited LPS-induced TNF-α expression in mac-
rophages. In our study, exendin-4 inhibited LPS-induced
TNF-α expression of macrophages. Because TNF-α induces
osteoclast formation and promotes RANKL expression in
stromal cells, our results suggest that the in vivo inhibition
of LPS-induced osteoclast formation by exendin-4 may be
the result of inhibition of LPS-induced TNF-α expression in
macrophages and subsequent suppression of RANKL expres-
sion in stromal cells.
5. Conclusions
In conclusion, our results suggested that exendin-4 can
inhibit LPS-induced osteoclast formation and bone resorp-
tion in vivo. The underlying mechanism may be related to
its inhibition in the production of LPS-induced TNF-α in
macrophages but not related to its direct effect on osteoclast
precursors or RANKL expression in stromal cells.
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Figure 5: Exendin-4 inhibited LPS-induced expression of TNF-α in
macrophages. TNF-α mRNA levels in macrophages were detected
by real-time RT-PCR. Total RNA was isolated from macrophages
cultured with PBS, LPS with or without exendin-4, and exendin-4
alone. TNF-α mRNA levels were normalized to the levels of
GAPDH. Statistical significance of differences was determined by
Scheffe’s test (n = 4; ∗p < 0 05, ∗∗P < 0 01).
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